An official website of the United States government
Musculoskeletal System
Topics
- Arthritis
- Cachexia
- Childhood Leukemia
- Congenital Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy
- Lymphoma
- Myasthenia Gravis
- Myotonic Dystrophy
- Osteoarthritis
- Osteogenesis Imperfecta
- Osteoporosis
- Rheumatoid Arthritis
- Sarcopenia
- Temporomandibular Muscle/Joint Disorder (TMJD)
- Muscular Dystrophy
- Hodgkin's Disease
- Paget's Disease
Showing 1-2 of 2
Retired Program: Accelerating Medicines Partnership® Program for Type 2 Diabetes (AMP T2D) - NIDDK
- Home
- About NIDDK
- Research Areas
- Diabetes
- Accelerating Medicines Partnership® Program for Type 2 Diabetes (AMP T2D)
Related Topics
Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD)
Accelerating Alzheimer's Research and Drug Development
The Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease.
Accelerating Medicines Partnership (AMP)
Scientific Contacts for AMP AD
Laurie Ryan, Ph.D.
Email Laurie Ryan